Virginia Commonwealth University Scientists Report Anti-Inflammatory Effect of Aradigm Corporation's Inhaled Liposomal Ciprofloxacin

Published: Oct 16, 2012

HAYWARD, Calif.--(BUSINESS WIRE)--Today at the annual meeting of the American Association of Pharmaceutical Scientists (AAPS) in Chicago, IL, scientists from the Virginia Commonwealth University (Richmond, VA) will report findings about the anti-inflammatory effects of Aradigm Corporation’s (OTCBB:ARDM) (the “Company”) inhaled ciprofloxacin in human bronchial lung cells stimulated by the lipopolysaccharide (LPS) produced by Pseudomonas aeruginosa.

Back to news